赫赛汀联合干扰能对肾癌细胞的杀伤抑制作用  

Influence of trastuzumab with IFNα-2b on HER2 and MRP1 of ACHN

作　　者：胡志全[1] 王家菁[1] 叶章群[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院泌尿外科,武汉430030

出　　处：《中华实验外科杂志》2005年第8期960-961,共2页Chinese Journal of Experimental Surgery

摘　　要：目的了解赫赛汀联合干扰能(IFNα2b)对肾癌细胞在体外的杀伤抑制作用,同时检测肾癌细胞在药物作用前后表皮生长因子受体2(HER2)、多药耐药相关蛋白1(MRP1)的表达情况。方法肾癌细胞系通过细胞培养技术进行培养,用噻唑蓝(MTT)法观察赫赛汀联合IFNα2b对该细胞系的抑制杀伤效果,过河实验检测癌细胞的侵袭能力,进而运用链霉抗生物素过氧化物酶免疫组织化学(SP)法对HER2、MRP1表达情况进行测定。结果赫赛汀联合IFNα2b对肾癌细胞的生长抑制及耐药性呈时间和剂量依赖性。经药物处理后,HER2、MRP1表达明显下降,由用药前的62.82%、69.42%降到用药后的24.35%、16.87%(P<0.05)。结论联合用药能有效抑制肾癌细胞的生长,对瘤细胞的耐药性也有一定的逆转作用。Objective To study the influence of trastuzumab and IFNα-2b on HER2, MRP1 of ACHN in vitro. Methods Human caucasian kidney adenocarcinoma （ACHN） cell line of renal cell carcinoma （RCC） was cultured by cell culture technique. The tetrazolium-based colorimetric assay was used to evaluate the growth inhibitory effect of trastuzumab and IFNα-2b. The invasiveness of the cell line wasdetermined by the crossing-river test. SP method was used to detect the expression of HER2, MRP1 of the cells. Results Trastuzumab showed the inhibitory effect on growth and multi-drug resistance（MDR） in RCC from 40 μg/L or 24 h in time- and dose-dependent manner. After treatment with Trastuzumab and/or IFNα-2b, the expression of HER2, MRP1 genes of RCC was decreased significantly,from62.82%,69.42% to 24.35%, 16.87% respectively （P〈0.05）.Conclusion Trastuzumab and IFNα-2b can inhibit the proliferation of RCC and the expression of HER2, MRP1 in ACHN, and deteriorate tolerance of the cell lines.

关 键 词：赫赛汀 联合用药 干扰能 肾癌 肿瘤细胞 杀伤抑制作用 耐药性 

分 类 号：R737.11[医药卫生—肿瘤] R979.1[医药卫生—临床医学]